A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol)

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 11, 2009, Pages 1193-1201

  Thorpe, M P ^b   Ehrenpreis, E D ^a,c   Putt, K S ^b   Hannon, B ^b  

^a Highland Park Hospital   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ARTICLE; COLON MOTILITY; COMPUTER MODEL; DEFECATION; DELAYED RELEASE FORMULATION; DESCENDING COLON; DOSAGE SCHEDULE COMPARISON; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; PRIORITY JOURNAL; RECTUM; SIGMOID; TRANSVERSE COLON;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLON; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MESALAMINE; MODELS, BIOLOGICAL; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 66149146569     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03968.x     Document Type: Article

References (39)

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006 12 : S3 8. (Pubitemid 43068428)
2. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-durgs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003 17 : 29 42. (Pubitemid 36140432)
3. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006 23 : 577 85.
4. Eisen SA, Miller DK, Woodward RS, Spitznagel TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Int Med 1990 150 : 1881 4. (Pubitemid 20316533)
5. Kruse W, Rampmater G, Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharm Ther 1994 32 : 452 7. (Pubitemid 24277054)
6. Pullar T, Birtwell AJ, Wiles PJ, Hay A, Feely MP. Use of a pharmacological indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily. Clin Pharm Ther 1988 44 : 540 55. (Pubitemid 19002867)
7. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. Limited exposure of the healthy distal colon to orally-dosed formulations is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000 14 : 155 61. (Pubitemid 30088291)
8. Klotz U. Clinical pharmacokinetics of sulfasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 1985 10 : 285 302. (Pubitemid 15005992)
9. Bondesen S. Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. Pharmacol Toxicol 1997 81 (Suppl. 2 1 28. (Pubitemid 27473945)
10. Christensen LA. 5-Aminosalicylic acid containing drugs. Delivery, fate and possible clinical implications in man. Dan Med Bull 2000 47 : 20 41. (Pubitemid 30082269)
11. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000 47 (3 410 4.
12. Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5- aminosalicylic acid is useful for estimating therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 2001 7 : 221 5. (Pubitemid 32776515)
13. Johnston MD, Edwards CM, Bodmer WF, Maini PK, Chapman SJ. Examples of mathematical modeling: Tales from the crypt. Cell Cycle 2007 6 : 2106 12. (Pubitemid 47450409)
14. Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahar M. PET kinetic analysis - compartmental model. Ann Nucl Med 2006 20 : 583 8.
15. Green MH, Green JB, Berg T, Norum KR, Blomhoff R. Vitamin A metabolism in rat liver: a kinetic model. Am J Physiol 1993 264 : G509 21. (Pubitemid 23116861)
16. Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003 17 : 395 402. (Pubitemid 36259402)
17. Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003 17 : 1163 9. (Pubitemid 36605753)
18. Hebden JM, Gilchrist PJ, Blackshaw E, et al. Night-time quiescence and morning activation in the human colon: Effect on transit of dispersed and large single unit formulations. Eur J Gastroenterol Hepatol 1999 11 : 1379 85. (Pubitemid 30009343)
19. Krogh K, Olsen N, Christensen P, Madsen JL, Laurberg S. Colorectal transport in normal defaecation. Colorectal Dis 2003 5 : 185 92. (Pubitemid 36442843)
20. Zhou SY, Fleisher D, Pao LH, Li C, Winward B, Zimmermann EM. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999 27 : 479 85. (Pubitemid 29177641)
21. Black DA, Ainley CC, Senapati A, Thompson RP. Transit time in ulcerative proctitis. Scand J Gastroenterol 1987 22 : 872 6.
22. Allison MC, Dick R, Pounder RE. A controlled study of faecal distribution in ulcerative colitis and proctitis. Scand J Gastroenterol 1987 22 : 1277 80. (Pubitemid 18031904)
23. Ejderhamn J, Rafter JJ, Strandvik B. Faecal bile acid excretion in children with inflammatory bowel disease. Gut 1991 32 : 1346 51.
24. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000 14 : 155 61. (Pubitemid 30088291)
25. Hussain FN, Ajjan RA, Kapur K, Moustafa M, Riley SA. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001 15 : 53 62. (Pubitemid 32055586)
26. Bondesen S, Hegnhoj J, Larsen F, Hansen SH, Hansen CP, Rasmussen SN. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. Dig Dis Sci 1991 36 : 1735 40.
27. Corey AE, Rose GM, Conlkin JD. Bioavailability of single and multiple doses of enteric-coated mesalazine and sulphasalazine. J Int Med Res 1990 18 : 441 53.
28. Devane J, Mulligan S, Martin M. Distal ileum and colon: targeted sites for 5-ASA release. Eur J Drug Metab Pharmacokinet 1991 3 : 300 3.
29. Goebell H, Klotz U, Nehlsen B, Layer P. Oroileal transit of slow release 5- aminosalicylic acid. Gut 1993 34 : 669 75. (Pubitemid 23146894)
30. Herzog R, Leuschner J. Experimental studies on the pharmacokinetics and toxicity of 5- aminosalicylic acid-O-sulfate following local and systemic application. Arzneimittelforschung 1995 45 : 300 3.
31. Hussain FN, Ajjan RA, Riley SA. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Br J Clin Pharmacol 2000 49 : 323 30. (Pubitemid 30195274)
32. Jacobsen BA, Abildgaard K, Rasmussen HH, et al. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand J Gastroenterol 1991 26 : 374 8.
33. Klotz U, Stracciari GL. Steady state disposition of 5-amino-salicylic acid following oral dosing. Arzneimittelforschung 1993 43 : 1357 9. (Pubitemid 24009945)
34. Norlander B, Gotthard R, Strom M. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. Aliment Pharmacol Ther 1989 3 : 333 42. (Pubitemid 20118790)
35. Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982 83 : 1062 70.
36. Ryde EM, Ahnfelt NO. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Eur J Clin Pharmacol 1988 34 : 481 8. (Pubitemid 18156443)
37. Sandberg-Gertzen H, Ryde M, Jarnerot G. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol 1983 18 : 107 11. (Pubitemid 13138112)
38. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000 95 : 1263 76. (Pubitemid 30263523)
39. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American college of gastroenterology, practice parameters committee. Am J Gastroenterol 2004 99 : 1371 85. (Pubitemid 39062279)